Working… Menu

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04791839
Recruitment Status : Recruiting
First Posted : March 10, 2021
Last Update Posted : September 17, 2021
Arcus Biosciences, Inc.
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 30, 2023
Estimated Study Completion Date : February 28, 2028